Chinese Drugmaker Expands Pharma Production Facility

Changzhou Qianhong Bio-pharma started the second phase of construction at its pharmaceuticals production facility in Changzhou National Hi-Tech District. With an investment of 1 billion yuan (~$150 million), phase two adds 200 million tablets and 60 million injections to production as well as making molecular diagnosis reagents available for use by 20 million people. Changzhou government officials including Liang Yibo and Yan Jun took part in the groundbreaking ceremony.
 
Changzhou Qianhong Bio-pharma, a leading biochemical maker of polysaccharides and enzymes drugs, is a major manufacturer of pancreatic kininogenase, heparin sodium and low molecular weight heparin, as well as compound digestive enzyme preparations and asparaginase, all of which had, prior to the roll out of the phase one facility, never been produced in China. The entire drug lineup, according to the company, meets international standards in terms of production technologies and quality. Several products have been granted quality certifications by governing bodies in the U.S., the EU and Japan. The company has set up an international marketing network, with products being sold in more than 20 provinces and cities across China as well as exported to markets abroad.
 
The 1.2 billion-yuan phase one project, which is already in operation, generated sales revenue of 1,070 million yuan in 2017. Phase two, in line with international standards, will focus on the research and development of innovative and first-of-its-class-in-China biological drugs with its own intellectual property rights, with the aim of treating patients with critical illnesses such as cancers as well as cardiovascular and cerebrovascular diseases.